207 related articles for article (PubMed ID: 36136102)
21. Combined whole-body dynamic and static PET/CT with low-dose [
Sachpekidis C; Pan L; Groezinger M; Strauss DS; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2137-2150. PubMed ID: 38286936
[TBL] [Abstract][Full Text] [Related]
22. The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions.
Afshar-Oromieh A; Hetzheim H; Kratochwil C; Benesova M; Eder M; Neels OC; Eisenhut M; Kübler W; Holland-Letz T; Giesel FL; Mier W; Kopka K; Haberkorn U
J Nucl Med; 2015 Nov; 56(11):1697-705. PubMed ID: 26294298
[TBL] [Abstract][Full Text] [Related]
23. A pilot study of
Wang G; Zhou M; Zang J; Jiang Y; Chen X; Zhu Z; Chen X
EJNMMI Res; 2022 Aug; 12(1):52. PubMed ID: 35984529
[TBL] [Abstract][Full Text] [Related]
24. 68 Ga-PSMA-11 PET/CT Imaging in Brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract][Full Text] [Related]
25. [
Peters SMB; Hofferber R; Privé BM; de Bakker M; Gotthardt M; Janssen M; de Lange F; Muselaers CHJ; Mehra N; Witjes JA; Costa PF; Nagarajah J; Konijnenberg MW; Jentzen W
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1101-1112. PubMed ID: 34623453
[TBL] [Abstract][Full Text] [Related]
26. Analysis of Pros and Cons in Using [
Maisto C; Aurilio M; Morisco A; de Marino R; Buonanno Recchimuzzo MJ; Carideo L; D'Ambrosio L; Di Gennaro F; Esposito A; Gaballo P; Pirozzi Palmese V; Porfidia V; Raddi M; Rossi A; Squame E; Lastoria S
Molecules; 2022 Jun; 27(12):. PubMed ID: 35744985
[TBL] [Abstract][Full Text] [Related]
27. Value of Combined PET Imaging with [
Khreish F; Ribbat K; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Schreckenberger M; Ezziddin S; Rosar F
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439287
[TBL] [Abstract][Full Text] [Related]
28. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions.
Wang J; Zang J; Wang H; Liu Q; Li F; Lin Y; Huo L; Jacobson O; Niu G; Fan X; Zhu Z; Chen X
Clin Nucl Med; 2019 Jun; 44(6):431-438. PubMed ID: 30985422
[TBL] [Abstract][Full Text] [Related]
29. Dual-Tracer PET/CT Protocol with [
Roth KS; Voltin CA; van Heek L; Wegen S; Schomäcker K; Fischer T; Marnitz S; Drzezga A; Kobe C
J Nucl Med; 2022 Nov; 63(11):1683-1686. PubMed ID: 35422446
[TBL] [Abstract][Full Text] [Related]
30. Early molecular imaging response assessment based on determination of total viable tumor burden in [
Rosar F; Wenner F; Khreish F; Dewes S; Wagenpfeil G; Hoffmann MA; Schreckenberger M; Bartholomä M; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1584-1594. PubMed ID: 34725725
[TBL] [Abstract][Full Text] [Related]
31. [
Rosar F; Schaefer-Schuler A; Bartholomä M; Maus S; Petto S; Burgard C; Privé BM; Franssen GM; Derks YHW; Nagarajah J; Khreish F; Ezziddin S
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4736-4747. PubMed ID: 35930033
[TBL] [Abstract][Full Text] [Related]
32. Theranostics of Metastatic Prostate Cancer Applying
Mirzaei S; Mohammed F; Zandieh S
Curr Radiopharm; 2021; 14(4):354-358. PubMed ID: 32900357
[TBL] [Abstract][Full Text] [Related]
33.
De Man K; Van Laeken N; Schelfhout V; Fendler WP; Lambert B; Kersemans K; Piron S; Lumen N; Decaestecker K; Fonteyne V; Delrue L; De Vos F; Ost P
Eur Urol; 2022 Nov; 82(5):501-509. PubMed ID: 35690515
[TBL] [Abstract][Full Text] [Related]
34. Imaging of Prostate-Specific Membrane Antigen Expression in Metastatic Differentiated Thyroid Cancer Using 68Ga-HBED-CC-PSMA PET/CT.
Lütje S; Gomez B; Cohnen J; Umutlu L; Gotthardt M; Poeppel TD; Bockisch A; Rosenbaum-Krumme S
Clin Nucl Med; 2017 Jan; 42(1):20-25. PubMed ID: 27846003
[TBL] [Abstract][Full Text] [Related]
35. A Prospective Trial of
Wang B; Liu C; Wei Y; Meng J; Zhang Y; Gan H; Xu X; Wan F; Pan J; Ma X; Hu S; Freedland SJ; Song S; Ye D; Zhu Y
Clin Cancer Res; 2020 Sep; 26(17):4551-4558. PubMed ID: 32527944
[TBL] [Abstract][Full Text] [Related]
36. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
37. Head-to-head comparison of [
Wang G; Li L; Wang J; Zang J; Chen J; Xiao Y; Fan X; Zhu L; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1499-1509. PubMed ID: 36600099
[TBL] [Abstract][Full Text] [Related]
38. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
39. A Comparison of 18 F-FDG PET/CT and 68 Ga-PSMA PET/CT in Detecting Osteonecrosis of the Jaw in a Patient With Prostate Cancer.
Öztürk AE; Şahin R; Ergül N; Çermik TF; Arslan E
Clin Nucl Med; 2024 Feb; 49(2):e68-e69. PubMed ID: 38170920
[TBL] [Abstract][Full Text] [Related]
40. Biodistribution and radiation dosimetry of multiple tracers on total-body positron emission tomography/computed tomography.
Li L; Wan L; Zhao H; Wang C; Wei W; Liu J
Quant Imaging Med Surg; 2023 Aug; 13(8):5182-5194. PubMed ID: 37581077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]